Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nova Scotia Becomes Sixth Jurisdiction To Implement Biosimilar Switching

Policy Welcomed By Trade And Advocacy Groups

Executive Summary

Citizens enrolled on Nova Scotia’s Pharmacare programs have 12 months to switch to biosimilar versions of certain biologic drugs, including some insulins and medications used to treat Crohn’s disease and rheumatoid arthritis. 

You may also be interested in...



Biosimilars ‘Policy Salad’ Setting Back Sector, Canadian Study Says

The Ontario Drug Policy Research Network has released a new study on biosimilar uptake across Canada, where the use of biosimilars is relatively low in comparison to other OECD countries.

Biosimilars ‘Policy Salad’ Setting Back Sector, Canadian Study Says

The Ontario Drug Policy Research Network has released a new study on biosimilar uptake across Canada, where the use of biosimilars is relatively low in comparison to other OECD countries.

What’s Next? Five Things To Look Out For In May

This month, Eli Lilly’s Alimta blockbuster will lose patent protection in the US, while Teva – which will also publish its Q1 financial results – will see Bristol Myers Squibb begin its appeal process against a key UK ruling involving the originator’s Eliquis (apixaban) anticoagulant.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB151625

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel